Adriana Aurelia Chis,Carmen Maximiliana Dobrea,Anca Maria Arseniu,Adina Frum,Luca-Liviu Rus,Gabriela Cormos,Cecilia Georgescu,Claudiu Morgovan,Anca Butuca,Felicia Gabriela Gligor,Andreea Loredana Vonica-Tincu
Abstract:Antineoplastic therapy is one of the main research themes of this century. Modern approaches have been implemented to target and heighten the effect of cytostatic drugs on tumors and diminish their general/unspecific toxicity. In this context, antibody–drug conjugates (ADCs) represent a promising and successful strategy. The aim of this review was to assess different aspects regarding ADCs. They were presented from a chemical and a pharmacological perspective and aspects like structure, conjugation and development particularities alongside effects, clinical trials, safety issues and perspectives and challenges for future use of these drugs were discussed. Representative examples include but are not limited to the following main structural components of ADCs: monoclonal antibodies (trastuzumab, brentuximab), linkers (pH-sensitive, reduction-sensitive, peptide-based, phosphate-based, and others), and payloads (doxorubicin, emtansine, ravtansine, calicheamicin). Regarding pharmacotherapy success, the high effectiveness expectation associated with ADC treatment is supported by the large number of ongoing clinical trials. Major aspects such as development strategies are first discussed, advantages and disadvantages, safety and efficacy, offering a retrospective insight on the subject. The second part of the review is prospective, focusing on various plans to overcome the previously identified difficulties.
What problem does this paper attempt to address?
This paper discusses the development and prospects of Antibody-Drug Conjugates (ADCs) in anticancer therapy. ADCs are a novel targeted therapy consisting of monoclonal antibodies, linkers, and cytotoxic payloads, aiming to improve the efficacy of chemotherapy drugs and reduce toxicity to normal cells by specifically targeting tumor cells.
The article first introduces the history of cancer treatment, pointing out that despite over 80 years of history, cancer remains a global major disease. Modern therapies attempt to overcome the limitations of traditional chemotherapy, such as nonspecific toxicity, drug resistance, and systemic toxicity. ADCs, as a targeted therapy, use monoclonal antibodies to deliver drugs precisely to tumor cells, reducing side effects.
The paper reviews the development of ADCs, from early concepts to over 100 different stages of ADC drugs in clinical trials. Some ADC drugs have been approved for the treatment of hematological malignancies and solid tumors, such as T-DM1 and brentuximab vedotin. However, ADCs also face challenges, such as the instability of linkers that may result in premature release of toxic payloads, and the expression of target antigens on non-malignant cells, which may lead to toxicity.
The article discusses in detail the structure of ADCs (including monoclonal antibodies, linkers, and cytotoxic payloads), clinical trials, safety issues, and future development strategies. The authors also list different types of linkers (such as pH-sensitive, reduction-sensitive, peptide-based, and phosphate-based linkers), their roles and release mechanisms in ADCs, and provide examples of various types of ADC structures and their behavior in vivo.
In conclusion, this review paper aims to comprehensively evaluate ADCs from a chemical, pharmacological, and clinical perspective, discussing their advantages, challenges, and possible solutions, to provide guidance for future cancer treatment research.